Literature DB >> 1267575

Serum dopamine-beta-hydroxylase activity in the affective psychoses and schizophrenia. Decreased activity in unipolar psychotically depressed patients.

H Y Meltzer, H W Cho, B J Carroll, P Russo.   

Abstract

Serum dopamine-beta-hydroxylase (DBH) activity was studied in 125 psychiatric patients and 73 normal controls. Serum DBH activity in schizophrenic, bipolar manic, and neurotic depressive patients was not significantly different from that in controls. Although serum DBH activity in unipolar and bipolar depressed patients was also not significantly different from that in controls, the subgroup of psychotically depressed unipolar patients had significantly lower serum DBH levels than controls did. Serum DBH activity in bipolar psychotically depressed patients also tended to be low, but was not significantly less than in controls. Serum DBH activity in the patient group usually did not increase in the immediate period following successful treatment with drugs or electroconvulsive therapy, indicating that basal levels of serum DBH activity in psychiatric patients are not state-dependent. Low serum DBH levels in psychotically depressed patients must be verified in an independent group of patients before its significance can be appreciated. Our findings could be the result of the study of an atypical group of psychotically depressed patients.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1267575     DOI: 10.1001/archpsyc.1976.01770050047007

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  13 in total

Review 1.  Psychotic major depression: a benefit-risk assessment of treatment options.

Authors:  Audrey R Tyrka; Lawrence H Price; Marcelo F Mello; Andrea F Mello; Linda L Carpenter
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Neurobiological characterization of bipolar affective disorders : a focus on tardive dyskinesia and soft neurological signs in relation to serum dopamine Beta hydroxylase activity.

Authors:  U Goswami; S Basu; U Khastgir; U Kumar; R Chandrasekaran; B N Gangadhar; R Sagar; J S Bapna; S M Channabasavanna; P B Moore; I N Ferrier
Journal:  Indian J Psychiatry       Date:  1998-07       Impact factor: 1.759

3.  Vulnerability to disulfiram psychosis.

Authors:  H A Nasrallah
Journal:  West J Med       Date:  1979-06

4.  Atypical psychotic symptoms in a Hispanic population: diagnostic dilemmas and implications for treatment.

Authors:  David Mischoulon; Isabel T Lagomasino; Chris Harmon
Journal:  Psychiatry (Edgmont)       Date:  2005-10

5.  Clinical features of methamphetamine-induced paranoia and preliminary genetic association with DBH-1021C→T in a Thai treatment cohort.

Authors:  Rasmon Kalayasiri; Viroj Verachai; Joel Gelernter; Apiwat Mutirangura; Robert T Malison
Journal:  Addiction       Date:  2014-03-17       Impact factor: 6.526

Review 6.  Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology.

Authors:  J F Cubells; C P Zabetian
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

7.  Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.

Authors:  Thomas R Kosten; Guiying Wu; Wen Huang; Mark J Harding; Sara C Hamon; Jaakko Lappalainen; David A Nielsen
Journal:  Biol Psychiatry       Date:  2012-08-18       Impact factor: 13.382

8.  A functional dopamine-beta-hydroxylase gene promoter polymorphism is associated with impulsive personality styles, but not with affective disorders.

Authors:  C Hess; A Reif; A Strobel; A Boreatti-Hümmer; M Heine; K-P Lesch; C P Jacob
Journal:  J Neural Transm (Vienna)       Date:  2008-11-04       Impact factor: 3.575

9.  Serum dopamine-beta-hydroxylase activity: clinical applications in child psychiatry.

Authors:  J G Young; R M Kyprie; N T Ross; D J Cohen
Journal:  J Autism Dev Disord       Date:  1980-03

Review 10.  Dopamine and depression.

Authors:  A S Brown; S Gershon
Journal:  J Neural Transm Gen Sect       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.